[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349519-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349519-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-prevalence-of-the-ar-v7-variant-and-its-association-with-clinicopathologic-characteristics-in-non-prostatic-cancers-a-systematic-review","The prevalence of the AR-V7 variant and its association with clinicopathologic characteristics in non-prostatic cancers - a systematic review","","Androgen receptor splice variant 7 (AR-V7) is linked to resistance to androgen receptor-targeting therapies in prostate cancer, yet its frequency and clinical meaning in non-prostatic cancers are not well defined. A systematic review following PRISMA analyzed 34 studies comprising 4855 clinical cases and 60 cell lines. AR-V7 positivity occurred in 948/4855 (19.5%) but estimates varied across cancer types, designs, and detection methods. Breast cancer dominated incidence, with higher reported proportions in salivary duct carcinoma, hepatocellular carcinoma, and non-muscle-invasive bladder cancer, though based on smaller cohorts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-prevalence-of-the-ar-v7-variant-and-its-association-with-clinicopathologic-characteristics-in-non-prostatic-cancers-a-systematic-review/349519/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-prevalence-of-the-ar-v7-variant-and-its-association-with-clinicopathologic-characteristics-in-non-prostatic-cancers-a-systematic-review/349519.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was AR-V7 prevalence assessed in non-prostatic cancers?","Question",{"text":63,"@type":64},"AR-V7 prevalence was evaluated using a systematic review framework consistent with PRISMA guidelines across multiple studies and methods.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What proportion of clinical cases showed AR-V7 positivity overall?",{"text":68,"@type":64},"Across 34 included studies covering 4855 clinical cases, AR-V7 positivity was reported in 948 cases (19.5%).",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancer type accounted for most clinical cases and how did breast-cancer prevalence change after exclusions?",{"text":72,"@type":64},"Breast cancer contributed 4057 of 4855 cases (83.6%); after excluding the TCGA cohort where AR-V7 was inferred via splice-junction analysis, the prevalence of AR-V7-positive breast cancer decreased to 9%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349519,1790158751,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","The prevalence of the AR-V7 variant and its association with clinicopathologic characteristics in non-prostatic cancers—a systematic review  \nZaineh Alnoubani  1‡, Youssuf Khanafer  1‡, Adnan Fojnica  2, Emir Begagic  3, Inga Rose  4, Zoran Gatalica  4, Semir Vranic  1*  \n1 Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, PO Box 2713, 2713 Doha, Qatar 2 Institute of Virology, TUM School of Medicine, Technical University of Munich, Trogerstraße 30, 81675 Munich, Germany 3 Department of Neurosurgery, Cantonal Hospital Zenica, Crkvice 67, 72000 Zenica, Bosnia and Herzegovina 4 Reference Medicine, 4050 E Cotton Center Blvd Bldg 3 Suite 38, 85040 Phoenix, AZ, United States  \n*Corresponding author. Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, PO Box 2713, 2713 Doha, Qatar. E-mail: [semir.vranic@gmail.com](semir.vranic@gmail.com).  \n‡These two authors contributed equally to this work.  \nAbstract  \nAndrogen receptor splice variant 7 (AR-V7) is associated with resistance to androgen receptor-targeting therapies in prostate cancer, but its prevalence and clinical relevance in non-prostatic cancers remain incompletely characterized. A systematic review was conducted in accordance with PRISMA guidelines. Thirty-four studies, including 4855 clinical cases and 60 cell lines, were included. Overall, AR-V7 positivity was reported in 948/4855 clinical cases (19.5%); however, this represents a descriptive estimate across heterogeneous tumor types, study designs, and detection methods. Breast cancer accounted for 4057 of 4855 clinical cases (83.6%) and 815 of 948 AR-V7-positive cases (86.0%), with a within-cancer prevalence of 20.1%. However, after excluding the TCGA cohort in which AR-V7 was inferred through splice-junction analysis, the prevalence ofAR-V7-positive breast cancer decreased to 9%. Higher tumor-specific proportions were observed in salivary duct carcinoma (55.2%), hepatocellular carcinoma (57.1%), and non-muscle-invasive bladder cancer (82.6%), but these estimates were based on smaller cohorts and should be interpreted cautiously. AR-V7 was present in several treatmentnaive non-prostatic cancers, suggesting that it may represent a preexisting molecular feature in selected contexts. Current evidence suggests that AR-V7 warrants further investigation as a candidate biomarker. Standardized detection methods and prospective studies are needed before its clinical utility can be established.  \nReceived: 31 March 2026. Revised: 9 July 2026. Accepted: 26 July 2026 © The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \nGraphical abstract  \nKeywords AR-V7, non-prostatic cancers, androgen receptor, therapeutic resistance, systematic review  \n1. Introduction  \nThe androgen receptor (AR) is a nuclear receptor that binds androgens such as testosterone and dihydrotestosterone. Upon activation through androgen binding, the AR translocates to the nucleus and regulates gene transcription, thereby modulating various physiological processes. These physiological processes differ based on sex and age. In men, AR signaling is essential for prostate development and function, as well as spermatogenesis and testosterone production, contributing to overall fertility [1] . In women, AR is expressed widely in the ovary, uterus, and breast, playing a central role in follicular development, ovulation, and mammary gland growth [2] .  \nAR signaling is a major driver of prostate cancer (PCa) [3] . Although androgen deprivation therapy (ADT) is initially  \neffective, many patients eventually develop castration-resistant prostate cancer (CRPC), typically wit","cbCaicrVGvqKaTcK","https://ap.wps.com/l/cbCaicrVGvqKaTcK","pdf",716074,14,"English","# Introduction\n## Androgen receptor biology and signaling\n## AR variants and emergence of AR-V7\n## AR-V7 as a predictive biomarker in prostate cancer\n## Emerging evidence in non-prostatic cancers (e.g., breast and salivary duct carcinoma)","[{\"question\":\"How was AR-V7 prevalence assessed in non-prostatic cancers?\",\"answer\":\"AR-V7 prevalence was evaluated using a systematic review framework consistent with PRISMA guidelines across multiple studies and methods.\"},{\"question\":\"What proportion of clinical cases showed AR-V7 positivity overall?\",\"answer\":\"Across 34 included studies covering 4855 clinical cases, AR-V7 positivity was reported in 948 cases (19.5%).\"},{\"question\":\"Which cancer type accounted for most clinical cases and how did breast-cancer prevalence change after exclusions?\",\"answer\":\"Breast cancer contributed 4057 of 4855 cases (83.6%); after excluding the TCGA cohort where AR-V7 was inferred via splice-junction analysis, the prevalence of AR-V7-positive breast cancer decreased to 9%.\"}]","The prevalence of the AR-V7 variant and its association with clinicopathologic characteristics in non-prostatic cancers - a systematic review | PDF",1790084129,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a828effef71bf0f6e060f2710ae3f025.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59951c545884aa857697b4b03f4e1497.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df19f99c726a344ecc3eb8f3f35fced6.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c823ee8fd92eced353142b9577157e33.webp",980,1287]